Publications by authors named "Mario Saltarelli"

Claim this Profile
A
Adaptive, dose-finding phase 2 trial evaluating the safety and efficacy of ABT-089 in mild to moderate Alzheimer disease.
Robert A Lenz, Yili L Pritchett, Scott M Berry, Daniel A Llano, Shu Han, Mario D Saltarelli

Alzheimer Dis Assoc Disord· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, double-blind, placebo-controlled phase 2 study of α4β2 agonist ABT-894 in adults with ADHD.
Earle E Bain, Weining Robieson, Yili Pritchett, Tushar Garimella, Walid Abi-Saab, Mario D Saltarelli

Neuropsychopharmacology· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized pilot study of the efficacy and safety of ABT-089, a novel α4β2 neuronal nicotinic receptor agonist, in adults with attention-deficit/hyperactivity disorder.
Earle E Bain, George Apostol, R Bart Sangal, Weining Z Robieson, Dawnelle L McNeill, Mario D Saltarelli

J Clin Psychiatry· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The scopolamine model as a pharmacodynamic marker in early drug development.
Robert A Lenz, Jeffrey D Baker, Charles Locke, Lynne E Rueter, Eric G Mohler, Mario D Saltarelli

Psychopharmacology (Berl)· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of the novel α₄β₂ neuronal nicotinic receptor partial agonist ABT-089 in adults with attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled crossover study.
George Apostol, Walid Abi-Saab, Christopher J Kratochvil, Lenard A Adler, Weining Z Robieson, Mario D Saltarelli

Psychopharmacology (Berl)· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A double-blind, randomized, placebo-controlled study of the dopamine D₃ receptor antagonist ABT-925 in patients with acute schizophrenia.
Laura Redden, Beatrice Rendenbach-Mueller, Walid M Abi-Saab, David A Katz, Armen Goenjian, Mario D Saltarelli

J Clin Psychopharmacol· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of ABT-089 in pediatric attention-deficit/hyperactivity disorder: results from two randomized placebo-controlled clinical trials.
Timothy E Wilens, Laura M Gault, Ann Childress, Christopher J Kratochvil, Lindsey Bensman, Mario D Saltarelli

J Am Acad Child Adolesc Psychiatry· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blockade of [11C](+)-PHNO binding in human subjects by the dopamine D3 receptor antagonist ABT-925.
Ariel Graff-Guerrero, Laura Redden, Walid Abi-Saab, David A Katz, Sylvain Houle, Mario D Saltarelli

Int J Neuropsychopharmacol· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
D3 receptor target engagement in humans with ABT-925 using [11C](+)-PHNO PET.
Mark Day, Earle Bain, Gerard Marek, Mario Saltarelli, Gerard B Fox

Int J Neuropsychopharmacol· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Divalproex sodium in children with partial seizures: 12-month safety study.
Robert A Lenz, Roy D Elterman, Weining Z Robieson, Namita V Vigna, Mario D Saltarelli

Pediatr Neurol· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sevoflurane formulation water content influences degradation by Lewis acids in vaporizers.
Evan D Kharasch, Gowdahalli N Subbarao, Keith R Cromack, Dennis A Stephens, Mario D Saltarelli

Anesth Analg· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A double-blind, randomized, placebo-controlled trial of divalproex extended-release in the treatment of bipolar disorder in children and adolescents.
Karen Dineen Wagner, Laura Redden, Robert A Kowatch, Timothy E Wilens, Scott Segal, Mario Saltarelli

J Am Acad Child Adolesc Psychiatry· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Divalproex ER combined with olanzapine or risperidone for treatment of acute exacerbations of schizophrenia.
Daniel E Casey, David G Daniel, Carol Tamminga, John M Kane, Tram Tran-Johnson, Mario Saltarelli

Neuropsychopharmacology· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety of divalproex sodium extended-release in children and adolescents with bipolar I disorder.
Laura Redden, Melissa DelBello, Karen Dineen Wagner, Timothy E Wilens, Shishuka Malhotra, Mario Saltarelli

J Child Adolesc Psychopharmacol· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and tolerability of divalproex sodium extended-release in the prophylaxis of migraine headaches: results of an open-label extension trial in adolescents.
George Apostol, Ann Pakalnis, Genevieve A Laforet, Weining Z Robieson, Evelyn Olson, Mario Saltarelli

Headache· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Divalproex sodium extended-release for the prophylaxis of migraine headache in adolescents: results of a stand-alone, long-term open-label safety study.
George Apostol, Donald W Lewis, Genevieve A Laforet, Weining Z Robieson, Julie M Fugate, Mario D Saltarelli

Headache· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Divalproex extended-release in adolescent migraine prophylaxis: results of a randomized, double-blind, placebo-controlled study.
George Apostol, Roger K Cady, Genevieve A Laforet, Weining Z Robieson, Evelyn Olson, Mario Saltarelli

Headache· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, placebo-controlled, multicenter study of divalproex sodium extended release in the treatment of acute mania.
Charles L Bowden, Alan C Swann, Joseph R Calabrese, Leon M Rubenfaer, Patricia J Wozniak, Mario Saltarelli

J Clin Psychiatry· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations.
Robert H Dworkin, Miroslav Backonja, Michael C Rowbotham, Robert R Allen, Charles R Argoff, Mario Saltarelli

Arch Neurol· November 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis